iDEL Therapeutics is a Dortmund-based startup focused on developing novel cancer therapeutics. Their core technology is a synthetic shuttle platform designed to deliver drugs directly into the cytosol of tumor cells, evading endosomal trapping and preventing degradation. This platform is compatible with both large and small molecules, including nanobodies and cytotoxic payloads, aiming to unlock historically undruggable intracellular targets and broaden therapeutic windows. The company is advancing two proprietary lead programs towards clinical evaluation, with a focus on addressing a range of solid tumors. iDEL Therapeutics also aims to create scalable value through partnerships.